INTRODUCTION
When the United States Food and Drug Administration (FDA) set up its fi rst standards for approving and testing antimicrobial agents, it did not foresee the possibility that drugs do not act in the plasma compartment. Meanwhile, this regulatory authority and the European Agency for the Evaluation of Medicinal Products (EMEA) have recognized that plasma concentrations of antimicrobial agents are of less relevance and thus they focused their recent attention on tissue concentrations. Tissue levels of antimicrobials are considered much more important for the prediction of clinical and microbial effi cacy. Thus, in vivo determination of pharmacokinetic profi les of drugs and endogenous substances at the site of action has become a major focus in research by industry and academia. The measurement of target site concentrations in lung remains an ongoing challenge because of the protected anatomical position and its high vulnerability. In this context the minimal invasive microdialysis (MD) technique, a well-established method for the determination of pharmacokinetics of a wide range of substances in various tissues, has been increasingly employed during the past few years. 1 , 2 Data from human and animal studies have highlighted the value of this new method for the description of continuous time-vs-concentration profi les of drugs and endogenous substances in the interstitial space fl uid of the lung. The present work sets out to review the current applications of MD in human and animal lung in vivo and compares the advantages and disadvantages of MD and other methods for the investigation of drug pharmacokinetics in lung.
TECHNICAL CHALLENGES OF LUNG MD
The principles of MD for clinical and animal studies in various human tissues have been described and reviewed in detail previously. [1] [2] [3] [4] [5] Briefl y, the basic principle of MD is to perfuse the implanted MD probe with a perfusate, ie, a physiologic liquid at a very slow rate ( Figure 1 ). Substances present in the interstitial space fl uid of the investigated site can diffuse into the perfusate through a semipermeable membrane and appear in the dialysate at an individually determined percentage called " recovery. " Afterward the concentration in the dialysate is chemically analyzed and by E601 use of the respective recovery-value the true concentration in the interstitial space fl uid can be calculated.
Although MD is a widely used technique for the measurement of drugs and metabolic substances in many different tissues, until now it has only been employed in about a dozen studies in lung. This might be related to the wide range of alternative techniques available for the determination of concentrations in lung tissue. Some of these techniques, such as collection of sputum or bronchial secretions, are considered noninvasive and can be performed in healthy volunteers. 6 , 7 In contrast, implementation of lung MD is not possible in healthy volunteers due to ethical objections. As described for animal studies, implantation of MD probes through the chest wall may lead to pneumothorax and collapse of the lung. 8 To avoid the risk of pneumothorax, the performance of thoracotomy is inevitable ( Figure 2 ) ; thereby limiting MD experiments in the human lung to elective thoracic surgery. [9] [10] [11] However, if the MD probe is properly implanted under direct vision during conventionally performed lung surgery, no adverse events or clinical complications related to MD have been reported. [9] [10] [11] Lung MD in clinical studies was performed in spontaneously breathing patients after the end of the surgical procedures. In these studies fl exible custom-made MD probes (Metalant AB, Stockholm, Sweden) with a total length of ~50 cm to allow for pulmonal movement due to respiration were employed. 10 The tip of the probes was made of a 0.6 × 50-mm polyether sulphone membrane in order to achieve high recovery rates (43% to 78%, dependent on the fl ow rate of the perfusion media), which allows for accurate calculation of in vivo concentrations. Although the probe is also in contact with alveoli, membrane exchange will not take place with alveolar air, but only with the fl uid phase. 10 Therefore, the concentrations in the samples will exclusively represent concentrations in the interstitial space and the alveolar lining fl uid.
Shorter MD probes have been shown to be suffi cient for small animals. In animal models performing lung MD, usually CMA 10 8, 12, 13 or CMA 20 probes [12] [13] [14] (both CMA Microdialysis, Solna, Sweden) with membrane lengths of 10 to 16 mm were used. Some animal studies performed lung MD during cardiopulmonary bypass with cardiac arrest. Due to the limited movement of the lung in this condition short MD probes might be also be suffi cient for larger animals. 14 However, employment of shorter MD probes has been shown to lead to substantial reduction of recovery rates, which might result in unreliable data. 8 
CURRENT FOCUS OF LUNG MD
The fi rst study reporting lung MD was published in 1991 and investigated the pharmacokinetics of theophylline in rats. 15 However, the majority of lung MD studies have been performed for the determination of time-vs-concentration profi les of antimicrobial agents. Lung concentrations of meropenem, piperacillin and cefpirome, cefpodoxime, cefaclor, faropenem, tobramycin, and gentamycin have been investigated by MD in humans or animals. 9-12 , 16-18 The increasing interest in the pharmacokinetics of antimicrobial drugs in the lung might be related to the fact that over 60% of infections at intensive care units are infections of the lower respiratory tract. 19 In addition, community-acquired 
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pneumonia has been identifi ed as the most common cause of death in the western world due to infectious diseases. 20 Failure of antibiotic therapy may be linked to bacterial resistance against antibiotics or impaired penetration of antimicrobial agents into the site of infection. [21] [22] [23] In contrast to other drugs, the importance of pharmacokinetic-pharmacodynamic relationships for antimicrobial and clinical effi cacy has been widely documented for antibiotics. 24 , 25 In addition, pneumonia is an infectious disease where a close correlation between the clinical outcome and pharmacokinetic-pharmacodynamic surrogate parameters was demonstrated for humans. 26 However, target site concentrations may be substantially lower than plasma concentrations and, therefore, regulatory authorities like the EMEA and the FDA recommend measuring target site concentrations of antimicrobials rather than plasma concentrations to predict outcome of anti-infective therapy. 27 , 28 Since MD is a wellestablished method for the measurement of free antibiotic concentrations at the site of infection, 4 , 5 it is not surprising that lung MD has mainly been performed to comply with the scientifi c and commercial interest in the pharmacokinetics of antimicrobials in the lower respiratory tract.
METHODICAL CONSIDERATIONS FOR DETERMINING CONCENTRATIONS OF ANTIMICROBIALS IN LUNG
Because of the anatomy and the histological structure of the lung, concentrations of drugs may vary within the organ. 29 , 30 Exact attribution of the measured concentrations to the different compartments in lung has been considered as a prerequisite for the interpretation of pharmacokinetics of antimicrobial agents in lung. 29 Early techniques investigating the ability of antibiotics to penetrate into the lower respiratory tract include sampling of sputum, 31 respiratory secretions, [32] [33] [34] [35] pleural fl uid 36 and surgical collection of whole lung tissue 33 , 37 and bronchial mucosa. 31 , 37 Since the fi rst application of bonchoalveolar lavage (BAL) in the late 1960s 38 the technique has been employed in numerous studies, and sampling of epithelial lining fl uid (ELF) [39] [40] [41] and alveolar macrophages 40 , 42 by BAL is currently most often employed for pharmacokinetic research in lung. In addition to these techniques, imaging procedures like planar gamma scintigraphy and positron emission tomography have been applied for the determination of distribution patterns in lung. 43 , 44 However, several major methodical problems limit the interpretation of data derived from all these methods:
• Finding a correlation between concentrations in the sample and the concentration at the target site.
To estimate the dilution rate due to the instilled fl uid during BAL, endogenous markers like urea are commonly used. However, a dilution of more than 100-fold is frequent and, therefore, calculation of the true concentration may sometimes be imprecise. 41 , 45 Several authors mentioned, that a potential source of error of investigating antibiotic concentrations by BAL may be the antibiotic release from alveolar macrophages in the sample. 30 , 46 , 47 This may lead to overestimation of actual active extracellular concentrations in the ELF.
• Correlating pharmacokinetic data to a specifi c anatomic site. Concentrations obtained with BAL represent average concentrations over a large segment of the lung, since saline may distribute freely throughout the bronchial system during lavage. However, signifi cant differences of antibiotic concentrations have been described between bronchial secretions and acini in the lower respiratory tract. 48 • Correlating pharmacokinetic data to a histological site. For biopsy with consecutively tissue homogenization admixture of concentrations of blood, and intracellular and extracellular contents is unavoidable. Analogically, also imaging procedures like scintigraphy and positron emission tomography are not able to discriminate between different histological compartments.
• Use of longitudinal data in order to obtain timeconcentration-profi les. Tissue biopsy lacks the ability to monitor dynamic changes in concentrations of drugs in a single subject and time-concentration profi les can only be derived by use of longitudinal pharmacoki netic data. Although BAL can be performed repeatedly in one subject, the standard lavage technique involves instillation of saline into the lung with consecutive aspiration of the lavage fl uid. Since each episode of lavage alters the composition of ELF, frequent sampling at short time intervals would falsify the results thereby limiting the ability of this technique to determine dynamic time-concentration-profi les. 45 • Discrimination between free, ie, microbiologically active and bound fraction. Various studies have demonstrated that only the unbound fraction of an antibiotic becomes microbiologically active. 49 Concentrations of antimicrobials obtained from homogenized tissues or by use of imaging techniques are not only an average of intracellular and extracellular concentrations, but include also those fractions of an antibiotic that are bound to interstitial proteins or intracellular and intercellular membrane structures. 18 In contrast, MD enables the continuous measurement of the unbound drug concentrations at an exact histological site, ie, the interstitial space fl uid. However, determination of antibiotic concentrations in lung by MD comprises also some limitations. In general, determination of meropenem and piperacillin by lung MD resulted in higher concentrations than corresponding C max values obtained with other methods. However, this might be attributed to the fact that apart from MD studies most C max values are determined from only 1 to 6 time points, which easily could miss the actual maximal concentration. In addition to the limited sampling time points, the lower concentrations of meropenem and piperacillin in lung and bronchial mucosa from biopsies can be explained by the fact that whole-tissue concentrations represent an average of concentrations of different compartments. Since the cellular penetration of beta-lactam antibiotics is poor, the concentrations in the interstitial fl uid can be expected to be higher than the observed concentration in biopsy homogenates. 52 In contrast, investigations of other classes of antibiotics like fl uoroquinolons or macrolides, which accumulate in cells, might result in higher concentrations in biopsy homogenates and ELF than in the interstitial space fl uid of lung. 40 , 53 , 54 Concentrations of meropenem determined in ELF are much more congruent with pharmacokinetic data obtained by MD than concentrations of piperacillin. 41 , 51 However, while meropenem was determined in ELF at 6 time points, piperacillin was measured only 5 hours after application of the drug, and the actual C max value of piperacillin in ELF was most probably not detected.
PREDICTION OF TARGET SITE CONCENTRATIONS IN LUNG BY MD IN OTHER TISSUES
As previously discussed, lung MD is more challenging than in peripheral tissues and is limited to animals or restricted patient populations. Therefore, clinicians ask for " surrogate tissues, " which allow for prediction of concentrations in the lung. Recently, 2 animal studies have been designed to compare the concentrations of the antibiotics cefpodoxime and cefaclor in peripheral tissue and lung by use of MD. 12 , 16 Due to the similar content of water in lung and skeletal muscle tissue, muscle tissue can be considered more suitable to represent conditions in the lung than subcutaneous adipose tissue. 55 Therefore, these studies simultaneously employed MD in skeletal muscle and lung tissue of rats in order to determine whether the more easily accessible skeletal muscle could be taken as a surrogate for concentrations in the lung. Both studies found that unbound concentrations in the interstitial space fl uid of skeletal muscle and lung tissue are descriptively identical ( Table 2 ) and suggested that concentrations in skeletal muscle may be reasonable predictors for concentrations in lung.
Based on the fact that cefpodoxime identically penetrated into skeletal muscle and lung tissue of rats, lung penetration of cefpodoxime in humans was estimated by employing MD in skeletal muscle of healthy volunteers. 12 However, this approach seems only justifi ed if the similar penetration into lung and skeletal muscle observed in rats may be translated to humans. Two different studies performing lung MD in patients undergoing thoracotomy determined simultaneously concentrations of piperacillin or meropenem in skeletal muscle tissue. 9 , 11 Another study investigating concentrations of cefpirome in lung tissue appears, due to identical dosing regimes, comparable to a previous study performing MD in skeletal muscle tissue. 10 , 56 Similar area under the concentration time curve (AUC) and C max values for lung and skeletal muscle tissue were found in these studies and indicated that also in humans the pharmacokinetics in lung tissue may be reasonably predicted by the concentrations in skeletal muscle tissue ( Table 2 ) .
For piperacillin and meropenem these results may be unexpected, because the MD probes were inserted into C max , Maximum concentration; BAL, b ronchoalveolar lavage; ELF, epithelial lining fl uid; ND, no data. *The number of sampling time points to determine C max is shown. In addition, the number of patient groups to obtain longitudinal pharmacokinetic data from different individuals is indicated.
pneumonic lung tissue, while healthy skeletal muscle tissue was used for comparison. However, although recent studies indicate that tissue penetration may be considerably lower in patients as compared with healthy subjects, this difference was rather attributed to septic conditions and intensive care measures than to local infl ammation. 21 , 22 , 56 , 57 Since sepsis was diagnosed in both studies, it is not surprising that AUC values in lung and skeletal muscle tissue were signifi cantly lower than in plasma, while no signifi cant difference between lung and skeletal muscle tissue was detected.
The presented studies indicate that penetration of antimicrobial agents into lung and peripheral tissue might be altered to a similar extent, and skeletal muscle tissue might rep resent a worthy surrogate to predict concentrations of antimicrobials in lung. However, until now this has only been shown for ␤ -lactams and cannot be transferred to other antimicrobial classes without further investigations. This is determined by looking at pathologies like cystic fi brosis with progressive destruction of airway structures and abundant production of thick purulent bronchial secretions have been described to E605 been investigated in 2 MD studies. 8 , 15 The fi rst study set out to determine changes in the recovery of theophylline in lung and blood of rats during the MD experiment. The second study investigated whether the time-concentration course in plasma refl ects the concentration of theophylline in the lung in rats and horses. Variation of recovery with time was considerably lower for lung tissue as compared with blood, suggesting that determination of the recovery rate at the beginning and the end of the experiment might suffi ciently describe the recovery of theophylline in lung. 15 After intravenous application of theophylline to rats and horses the free concentration in the lung was signifi cantly lower than corresponding free concentrations in serum in both species. 8 This was attributed to the metabolic degeneration of theophylline in the lung. 67
Determination of Metabolic Processes in Lung
Until now, the majority of MD studies investigating metabolic processes in vivo have been limited to brain research. [68] [69] [70] A recent MD study set out to evaluate changes of concentrations of metabolites in the lung during ischemic reperfusion injury. 14 Ischemic reperfusion injury of lung tissue after cardiac arrest occurs in virtually all patients undergoing cardiopulmonary bypass. 71 The potential of cariporide, a substance that has been shown to reduce acidosis due to ischemia, 72 to protect the lung from injury during cardiopulmonary bypass was evaluated. 14 Lung MD was used to measure concentrations of glycerol, ie, a marker refl ecting the breakdown of the membrane phospholipids, in lung tissue of pigs undergoing cardiac arrest. 68 , 69 Although no difference in ischemia/reperfusion injury between cariporide and placebo was detected, MD was suggested to be a promising tool for in vivo studies of metabolic processes in the lung.
Investigation of Pathophysiologic Changes in Lung
Mucociliary transport and clearance of particles and bacteria from the airway surface represents the fi rst line of defense against infections of the lower respiratory tract. Due to genetic disorders such as primary ciliary dyskinesia and cystic fi brosis this mechanical defense mechanism may be reduced, which results in higher incidence of respiratory infections in these patients. 73 , 74 Recently, lung MD was employed for the determination of mucociliary transport in normal and cystic fi brosis (CF) mice. 13 An MD probe was implanted into the lumen of the trachea and a small quantity of dye was placed on the surface of a distal smaller bronchus at a known distance to the tip of the MD probe. The rate of bronchial mucociliary transport was calculated as the time from dye deposition to its fi rst detection in the MD samples. Although in this study no signifi cant difference in mucociliary transport between normal and CF mice could infl uence penetration of antibiotics into the lung. 29 , 58 , 59 Without further investigation it is doubtful that concentrations in skeletal muscle tissue can predict the altered permeability of antimicrobials into lung in such con ditions. 58 , 59 
DETERMINATION OF ANTIBIOTIC CONCENTRATIONS IN THE ELF BY MD
Bacterial adherence in the bronchial mucosa is often the fi rst step of pulmonary involvement of respiratory tract infections. High antimicrobial concentrations in the mucosa and ELF might inhibit bacterial adhesion and subsequent tissue invasion. 29 , 46 Since the microbiologically active concentration of an antibiotic in the bronchial wall and in the ELF is the result of a complex and dynamic process, 60 usually a combination of bronchial mucosa biopsy and sampling of BAL is performed for the determination of bronchial pharmacokinetics. 61 The general limitations of BAL, especially its poor anatomical resolution and inability to discriminate between antimicrobially active and inactive drug, have been discussed in a previous section of the review. In contract to BAL, MD allows for the dynamic determination of the extracellular, nonprotein-bound concentration of an antibiotic and, therefore, intrabronchial MD seems to be an interesting alternative for determination of antimicrobials in the ELF.
Until now, only one study used MD to measure the concentration of the aminoglycosides tobramycin and gentamycin in ELF in vivo. 17 MD probes were implanted into the bronchial system of rats via tracheotomy. The mean penetration of tobramycin and gentamycin indicated by the AUC tissue / AUC plasma ratio (0.36 and 0.56, respectively) was comparable to results previously determined by BAL (0.45 and 0.67). 39 The similar results obtained by both methods can be attributed to the fact that aminoglycosides are known to exclusively distribute in the extracellular space fl uid. Therefore, concentrations obtained by BAL have not been diverted by effusion of intracellular amounts of drug as known for macrolides of fl uoroquinolons. 53 , 62 , 63 
RARE APPLICATIONS OF LUNG MD
Several studies employed MD to monitor non-anti-infective drugs, endogenous substances, and pathophysiologic processes in the lung.
Theophylline
Recently, the relationship between the concentration of theophylline and both its adverse and benefi cial bronchodilatory effects has been demonstrated. 64 , 65 However, similar to antibiotics, most data were obtained by determination of concentrations of theophylline in serum rather than at the target site in the lung. 66 Theophylline concentrations in lung have E606 be detected, this seems an interesting method for determination of mucociliary transport rates.
SUMMARY
Drug concentrations at the target site have been accepted to be more predictive for the effect of a drug than plasma concentrations. Currently, various methods for the determination of pharmacokinetics of antibiotics in the lower respiratory tract are available. Head-to-head comparison of maximal concentrations of antibiotics in the lower respiratory tract revealed high differences between methods.
MD was a more advantageous approach compared with conventional methods because of its higher anatomical resolution and the ability to obtain dynamic time-vs-concentration profi les within one subject. Additionally, in clinical studies MD proved to be a feasible and safe method to measure concentrations in human lung in vivo. However, depending on the pathogen the infection takes place at different compartments of the lower respiratory tract. Since concentrations might signifi cantly differ between these compartments, only the combination of different methods seems able to appropriately describe the pharmacokinetics at different sites of the respiratory tract.
In conclusion, MD has been shown to be a useful tool for determination of free extracellular concentration in both the interstitial space fl uid of lung and in the ELF. Alternative applications of lung MD indicate that MD might be also used for the measurement of a wide range of substances and might be a suitable method for the investigation of metabolism and pathophysiologic processes in the lung.
